Cnbx Pharmaceuticals Inc. Financials
CNBX
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM ~14.5:1 split | AUG 2025 3:1 split | AUG 2024 ~3.4:1 split | AUG 2023 ~7.2:1 split | AUG 2022 | AUG 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | ||||||
| Selling & Marketing | – | – | $0 | $0 | $0 | $0 |
| General & Administrative | $0 | $0 | $1 | $1 | $2 | $1 |
| Research & Development | – | $0 | $0 | $0 | $1 | $2 |
| Total Operating Expenses | $0 | $0 | $1 | $1 | $3 | $3 |
| Operating Income | -$0 | -$0 | -$1 | -$1 | -$3 | -$3 |
| Non-Operating | ||||||
| Net Interest Expense | – | -$0 | – | – | – | – |
| Other Non-Operating Income (Expense) | $0 | $0 | $0 | $0 | $1 | $1 |
| Net Income | ||||||
| Net Income | -$0 | -$0 | -$1 | -$4 | -$4 | -$3 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.05 | $0.02 | $0.00 |
| EPS (Basic) | $0.00 | $0.00 | -$0.02 | -$0.42 | -$3.59 | -$0.02 |
| EPS (Diluted) | $0.00 | $0.00 | -$0.02 | -$0.42 | -$3.59 | -$0.02 |
| Weighted Avg Shares (Basic) | 1.32B | 90.6M | 30.2M | 8.8M | 1.2M | 138.5M |
| Weighted Avg Shares (Diluted) | 1.32B | 90.6M | 30.2M | 8.8M | 1.2M | 138.5M |
| Shares Outstanding | 1.32B | 90.6M | 30.2M | 8.8M | 1.2M | 138.5M |
Cnbx Pharmaceuticals (CNBX) financials: revenue, profit and margins
Cnbx Pharmaceuticals (CNBX) generated about $0.00 in revenue and -$462,091.00 in net income over the trailing twelve months, growing at roughly 68.4% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Cnbx Pharmaceuticals's (CNBX) revenue?+
Cnbx Pharmaceuticals generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly 68.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Cnbx Pharmaceuticals profitable?+
Cnbx Pharmaceuticals reported about -$462,091.00 in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Cnbx Pharmaceuticals growing?+
Cnbx Pharmaceuticals's revenue has compounded at roughly 68.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside CNBX's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 17 Jun 2026, covering the period ending 31 May 2026, as reported to the SEC. Data last refreshed 14 Oct 2026. How this is calculated.
Fiscal year ends Aug.
Peers
Pharmaceutical Preparations · Pick stocks to compare with CNBX
Spot a number that looks wrong? Check it in CNBX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CNBX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.